Supplementary Table -Supplemental material for Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials

<p>Supplemental material, Supplementary Table for Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials by Rashmi B Halker Singh, Ernesto Aycardi, Marcelo E Bigal, Pippa S Loupe, Mirna McDonald and David W Dodick in Cephalalgia</p

sj-pdf-1-cep-10.1177_03331024221123081 - Supplemental material for Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey

Supplemental material, sj-pdf-1-cep-10.1177_03331024221123081 for Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey by Irene de Boer, Anna Ambrosini, Rashmi B Halker Singh, Betül Baykan, Dawn C Buse, Cristina Tassoreli, Rigmor H Jensen, Patricia Pozo-Rosich and Gisela M Terwindt in Cephalalgia</p